Articles > immunotherapy

Teplizumab Delayed Onset of Type 1 Diabetes By An Average of Two Years

The immunotherapy treatment disrupted the destruction of beta cells in adults and children who had two more type 1 diabetes-related autoantibodies and elevated glucose levels.